v3.25.2
Restructuring and Related Charges
6 Months Ended
Jun. 27, 2025
Restructuring and Related Activities [Abstract]  
Restructuring and Related Activities Disclosure [Text Block]
5.Restructuring and Related Charges
Through its restructuring programs, the Company seeks more cost-effective means to improve profitability and to respond to changes in its markets. As such, the Company may incur restructuring costs as a component of the Company’s operating costs. The restructuring program, authorized in 2021, allows for charges of $50.0 million to $100.0 million, and does not have pre-determined actions or a specified time period.
During the first quarter of 2024, the Company committed to a plan to cease commercialization and clinical development, and wind down production of StrataGraft®, included in the Specialty Brands segment, which was completed in the first quarter of 2025.
Net restructuring and related (credits) charges by segment were as follows:
Three Months EndedSix Months Ended
June 27,
2025
June 28,
2024
June 27,
2025
June 28,
2024
Specialty Brands$(0.2)$0.2 $(2.2)$10.4 
Net restructuring and related (credits) charges by program were comprised of the following:
Three Months EndedSix Months Ended
June 27,
2025
June 28,
2024
June 27,
2025
June 28,
2024
2021 Program$(0.2)$0.2 $(2.2)$10.4 
The following table summarizes the restructuring reserves, which are included in accrued and other current liabilities on the Company's unaudited condensed consolidated balance sheets:
2021 Program
SeveranceContract CostsTotal
Balance as of December 27, 2024$0.2 $1.1 $1.3 
Charges from continuing operations
— 0.1 0.1 
Changes in estimate from continuing operations
— (2.3)(2.3)
Cash (payments)/receipts
(0.2)1.1 0.9 
Balance as of June 27, 2025$— $— $— 
Cumulative net restructuring and related charges incurred for the 2021 program was as follows as of June 27, 2025:
2021 Program
Specialty Brands$8.3